newsfilter
← Latest News
GlobeNewswire·

Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study

STAMFORD, Conn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced it is a partner in the recently launched GUARDIAN study (Genomic Uniform-screening Against Rare Diseases In All Newborns), a collaboratio